BRCA1 carriers who underwent BO before age 45 years and received estrogen-alone HRT showed a nonsignificant yet numerical reduction of breast cancer risk (HR 0.47, 95% CI 0.20–1.15, P = 0.1), vis-à-vis their counterparts not taking HRT137 (Table 2). The gene discussed is BRCA1; the disease is breast cancer.